2023-503869-34-00CompletedPhase 1
A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with acute myeloid leukemia (AML) that has come back after treatment or cannot be cured or treated by any other known therapies, also called relapsed or refractory AML (R/R AML) and in patients with relapsed or refractory higher-risk myeloid dysplastic syndrome (R/R HR-MDS).
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Jun 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 9 Mar 2023
- Start date
- 15 Mar 2022
- Lead sponsor
- Celgene Corp.
- EU CT number
- 2023-503869-34-00
- EudraCT number
- 2020-005329-95
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Hospital Clinic de Barcelona | Barcelona | Spain | Completed |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Completed |
| Hospital Universitario De Salamanca | Salamanca | Spain | Completed |
| University Hospital Virgen Del Rocio S.L. | Sevilla | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.